<DOC>
	<DOC>NCT00494338</DOC>
	<brief_summary>A multi-center controlled, non-comparative open Phase II trial of docetaxel and celecoxib in patients with metastatic androgen independent prostate cancer where efficacy is measured by PSA response defined as a 50% reduction in PSA maintained on two consecutive evaluations at least 4 weeks apart.</brief_summary>
	<brief_title>Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Patients with histologically confirmed MAIPC Documented progressive disease in bone, soft tissue or PSA despite castrate levels of testosterone If LHRH agonist were used previously it must be kept Previous antiandrogen should be held at least 4 weeks for flutamida or cyproterone and 6 weeks for bycalumida Previous DES should be held for at least 4 weeks before partcipating in the trial Chemotherapy naive patients No prior radioisotope Less than 25% of bone marrow should be irradiated for prior palliative radiotherapy KPS&gt; 70% Adequate hematologic, hepatic and renal function Patients with serious medical illness History of significant active cardiac disease History of gastrointestinal ulceration, bleeding or perforation History of myocardial infarctin within past 12 months Allergy to sulfonamides or to celecoxib or history of urticaria to any NSAID The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Metastatic Androgen Independent Prostate Cancer (MAIPC)</keyword>
</DOC>